ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0103

The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative

Rachel Elam1, Sandeepkumar Gupta2, Omar Tolaymat2, Sowmya Vasan3, Carolyn Crandall4, Jean Wactawski-Wende5, Karen Johnson6 and Laura Carbone2, 1Augusta University, Evans, GA, 2Augusta University, Augusta, GA, 3WHI, Seattle, WA, 4UCLA, Los Angeles, CA, 5University of Buffalo, Buffalo, NY, 6University of Tennessee Health Sciences Center, Memphis, TN

Meeting: ACR Convergence 2020

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Fracture, osteoporosis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of rheumatoid arthritis (RA) including methotrexate, sulfasalazine and hydroxychloroquine are associated with incident fractures in postmenopausal women with RA.

Methods: Of the 161,808 postmenopausal women who were enrolled in the Women’s Health Initiative (WHI), all who self-reported at baseline a history of RA and had either a DMARD and/or a biologic use or presence of anti-cyclic citrullinated peptide (Anti-CCP) antibody were included as RA patients. There were too few users of standard triple therapy (methotrexate, sulfasalazine and hydroxychloroquine use (n=9)) to determine the association of standard triple therapy use with incident fractures. Therefore, incident fractures in postmenopausal women with RA following use of methotrexate, sulfasalazine and/or hydroxychloroquine alone or as “combination therapy” (methotrexate and sulfasalazine or methotrexate and hydroxychloroquine) were estimated by Cox proportional hazards models using hazard ratios (HR) and 95% confidence intervals (CI) after consideration of potential confounders.

Results: There were 1,201 postmenopausal women with RA enrolled in WHI included in these analyses, of which 74% were Caucasian, 17% were African American and 9% were of other or unknown race/ethnicity. Of the postmenopausal women with RA, 421 (35%) had not used either methotrexate, sulfasalazine or hydroxychloroquine while 519 (43%) had used methotrexate, 83 (7%) sulfasalazine and 363 (30%) hydroxychloroquine at some time during study follow-up. Over a median length of 6.46 years of follow-up, in multivariable adjusted models, no statistically significant association was found between methotrexate (HR 1.1 [95% CI 0.8-1.6]), sulfasalazine (HR 0.6 [95% CI 0.2-1.5]) or hydroxychloroquine use (HR 1.0 [95% CI 0.7-1.5]) and incident fractures or between combination therapy with methotrexate and sulfasalazine or methotrexate and hydroxychloroquine use (HR 0.9 [95% CI 0.5-1.6]) and incident fractures.

Conclusion:

In conclusion, use of methotrexate, sulfasalazine or hydroxychloroquine alone or in combination is not associated with incident fractures in postmenopausal women with RA. Postmenopausal women with RA receiving any component of triple therapy should not be expected to have any substantial reduction in fracture risk from use of these medications.


Disclosure: R. Elam, None; S. Gupta, None; O. Tolaymat, None; S. Vasan, None; C. Crandall, None; J. Wactawski-Wende, None; K. Johnson, None; L. Carbone, None.

To cite this abstract in AMA style:

Elam R, Gupta S, Tolaymat O, Vasan S, Crandall C, Wactawski-Wende J, Johnson K, Carbone L. The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-association-of-methotrexate-sulfasalazine-and-hydroxychloroquine-use-with-incident-fractures-in-postmenopausal-women-with-rheumatoid-arthritis-findings-from-the-womens-health-initiative/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-methotrexate-sulfasalazine-and-hydroxychloroquine-use-with-incident-fractures-in-postmenopausal-women-with-rheumatoid-arthritis-findings-from-the-womens-health-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology